XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of common stock reserved for future issuance

As of March 31, 2024, the Company had reserved shares of its common stock for future issuance as follows:

 

Shares
Reserved

 

Common stock options outstanding

 

 

4,798,794

 

Unvested restricted stock units

 

 

311,500

 

Available for future grants under the 2021 Equity Incentive Plan

 

 

4,296,163

 

Available for future grants under the 2021 Employee Stock Purchase Plan

 

 

780,098

 

Total shares of common stock reserved

 

 

10,186,555

 

 

Summary of the Company's stock option activity

A summary of the Company’s stock option activity and related information for the three months ended March 31, 2024 is as follows:

 

Options
Outstanding

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual Term (in years)

 

 

Aggregate
Intrinsic
Value (in thousands)

 

Outstanding at December 31, 2023

 

 

5,301,254

 

 

$

4.76

 

 

 

6.9

 

 

$

 

Forfeited/Expired

 

 

(502,460

)

 

$

4.85

 

 

 

 

 

 

 

Outstanding at March 31, 2024

 

 

4,798,794

 

 

$

4.75

 

 

 

6.9

 

 

$

 

Vested at March 31, 2024

 

 

3,105,675

 

 

$

4.90

 

 

 

6.4

 

 

$

 

Exercisable at March 31, 2024

 

 

3,369,189

 

 

$

4.90

 

 

 

6.4

 

 

$

 

Summary of RSU activities

RSUs consist of time-based units (TSUs), performance-based units (PSUs) and market-based units (MSUs). The following table summarizes RSU activities during the three months ended March 31, 2024:

 

Number of
RSUs

 

 

Weighted-Average
Grant Date
Fair Value

 

Unvested at December 31, 2023

 

 

326,500

 

 

$

5.90

 

Cancelled

 

 

(15,000

)

 

$

6.98

 

Unvested at March 31, 2024

 

 

311,500

 

 

$

5.85

 

Summary of Non-cash stock-based compensation expense recorded

The following table summarizes stock-based compensation expense, including expense associated with options, TSUs, MSUs and award modifications for unvested options, reflected in the consolidated statements of operations and comprehensive loss (in thousands):

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Research and development

 

$

253

 

 

$

473

 

General and administrative

 

 

825

 

 

 

684

 

Total

 

$

1,078

 

 

$

1,157